Shanghai Tasly Pharmaceutical

Shanghai Tasly Biopharmaceutical is a leading Chinese biotechnology company and a core subsidiary of the Tasly Holding Group, specializing in the development and commercialization of innovative biologics. The company's flagship product, Prouro (recombinant human prourokinase), is a widely used thrombolytic agent for the treatment of acute myocardial infarction in China. Beyond cardiovascular health, the company maintains a robust pipeline focused on oncology and autoimmune diseases, utilizing advanced recombinant protein and antibody engineering platforms. Shanghai Tasly Biopharmaceutical operates integrated R&D and GMP-certified manufacturing facilities in Shanghai, positioning itself as a key player in the modernization of biopharmaceuticals within the Chinese market.